Full Press Release Details
Pharmaceuticals was Chosen to Present Results of a GLP-1
Oral Administration Study at the Diabetes Technology Society's
Annual Meeting (November 5-7, 2008; San Francisco, California)
Israel - October 20, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com),
a developer of oral drug delivery systems, announced today that its poster
entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose
excursions in a porcine model," has been accepted for presentation at the
Diabetes Technology Society's Ninth Annual Meeting in San Francisco, California
between November 5-7, 2009.
selection of Oramed as one of the companies to present at the Diabetes
Technology Conference is a wonderful opportunity for us to demonstrate our
technology to the world's leading diabetes scientists," said Nadav Kidron,
abstract will be presented on Thursday November 5, 2009, at 5:30 PM. The poster
will be available for viewing throughout the conference.
information about the Diabetes Technology Society's Ninth Annual Meeting, please
information about Oramed Pharmaceuticals, please visit www.oramed.com
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit www.oramed.com
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking